HC Wainwright & Co. Maintains Buy on Day One Biopharmaceutical, Raises Price Target to $50
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andres Maldonado maintains a Buy rating on Day One Biopharmaceutical (NASDAQ:DAWN) and raises the price target from $45 to $50.
June 05, 2023 | 10:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Day One Biopharmaceutical and raises the price target from $45 to $50.
The news directly mentions Day One Biopharmaceutical (NASDAQ:DAWN) and the raised price target by HC Wainwright & Co. analyst Andres Maldonado. This positive analyst rating and increased price target may lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100